Pamela Hevener
Psychiatric/Mental Health · Staunton, VANPI 1548408529
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 577 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 23.8% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 577 payments — averaging $15.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Lundbeck LLC$941
- Alkermes, Inc.$793
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$695
- Johnson & Johnson$632
- Otsuka America Pharmaceutical, Inc.$593
- plus $3K from 22 others
What the payments were for
- Food & beverage$8,67399%
- Education$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 136 | $2,080 |
| Lundbeck LLC | 72 | $941 |
| Alkermes, Inc. | 49 | $793 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 68 | $695 |
| Johnson & Johnson | 28 | $632 |
| Otsuka America Pharmaceutical, Inc. | 48 | $593 |
| Neurocrine Biosciences, Inc. | 25 | $452 |
| Teva Pharmaceuticals USA, Inc. | 26 | $415 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $376 |
| Vanda Pharmaceuticals Inc. | 15 | $318 |
| Corium, LLC | 10 | $221 |
| Axsome Therapeutics, Inc. | 9 | $160 |
| Novo Nordisk | 9 | $159 |
| Sunovion Pharmaceuticals Inc. | 15 | $152 |
| Ironshore Pharmaceuticals Inc. | 7 | $143 |
| Noven Therapeutics, LLC | 9 | $130 |
| Supernus Pharmaceuticals, Inc. | 5 | $72 |
| Eisai Inc. | 3 | $60 |
| E.r. Squibb & Sons, L.L.C. | 3 | $59 |
| Avanir Pharmaceuticals, Inc. | 3 | $58 |
| Almatica Pharma LLC | 3 | $57 |
| Idorsia Pharmaceuticals US Inc | 3 | $43 |
| Bausch Health US, LLC | 2 | $42 |
| Collegium Pharmaceutical, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $16 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $13 |
| Noven Pharmaceuticals, Inc. | 1 | $12 |
| Jazz Pharmaceuticals Inc. | 1 | $11 |
How this compares
$8,723 in reported general payments places this provider in the 95th percentile of 1,003 psychiatric/mental health providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 24 | $202,602 |
| RexultiBrexpiprazole | 41 | $63,880 |
| VraylarCariprazine Hcl | 38 | $52,438 |
| CaplytaLumateperone Tosylate | 11 | $17,946 |
| SeroquelQuetiapine Fumarate | 18 | $15,915 |
| TrintellixVortioxetine Hydrobromide | 19 | $15,394 |
| Lurasidone Hcl | 58 | $14,990 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 129 | $7,767 |
| Asenapine Maleate | 25 | $6,130 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,277 |
| Lisdexamfetamine Dimesylate | 19 | $4,054 |
| Duloxetine Hcl | 173 | $4,029 |
| Aripiprazole | 58 | $3,539 |
| Vilazodone Hcl | 38 | $3,320 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 89 | $3,276 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $452 | $202,60224 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $593 | $63,88041 claims |
| AbbVieVraylar | $2,080 | $52,43838 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $376 | $19,67131 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $695 | $17,94611 claims |
| Lilly USA, LLCOlanzapine | $16 | $1,97559 claims |
| Almatica Pharma LLCSertraline Hcl | $57 | $1,32779 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,003 psychiatric/mental health providers in Virginia.
Other psychiatric/mental health in Staunton
- Brooks FloydStaunton$10K
- Justin RayChesapeake$127K
- Katia HallChesapeake$88K
- Christine GilmoreBedford$75K
- Sarah FaberNewport News$59K
- Kristine GarciaGlen Allen$46K
- Tonjanika BoydRichmond$40K
- Kirby PatmonRichmond$36K
- Juliana FroschAmherst$36K
- Derick ReedyNickelsville$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.